Israeli bio-tech Atox Bio announced that the US Food and Drug Administration has granted fast track designation to its lead product AB103, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI). Currently, there are no approved treatments for NSTI, which has a high mortality rate.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000784167&fid=1725
FDA fast-tracks Israeli tissues infection treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.